BioNTech’s (BNTX) “Buy” Rating Reiterated at The Goldman Sachs Group

BioNTech (NASDAQ:BNTX)‘s stock had its “buy” rating reiterated by analysts at The Goldman Sachs Group in a research note issued to investors on Wednesday,MarketScreener reports.

BNTX has been the subject of several other research reports. Leerink Partners downgraded shares of BioNTech from an “outperform” rating to a “market perform” rating and set a $113.00 price objective for the company. in a research report on Monday, February 2nd. Truist Financial set a $155.00 target price on BioNTech in a research report on Tuesday. Jefferies Financial Group cut their price target on BioNTech from $151.00 to $138.00 and set a “buy” rating on the stock in a research note on Tuesday. Morgan Stanley restated an “overweight” rating on shares of BioNTech in a research note on Tuesday. Finally, Berenberg Bank reaffirmed a “buy” rating on shares of BioNTech in a research report on Friday, January 23rd. Ten research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $136.00.

BioNTech Stock Performance

BioNTech stock opened at $83.89 on Wednesday. The company has a market cap of $18.89 billion, a price-to-earnings ratio of -31.90 and a beta of 1.51. BioNTech has a 12 month low of $79.52 and a 12 month high of $124.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.12 and a quick ratio of 7.02. The stock’s 50-day moving average is $106.73 and its 200-day moving average is $102.83.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Tuesday, March 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.18. BioNTech had a negative net margin of 17.91% and a negative return on equity of 3.03%. The firm had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $941.99 million. During the same quarter in the prior year, the company earned $1.08 EPS. The company’s revenue was down 23.7% on a year-over-year basis. Equities analysts anticipate that BioNTech will post -3.88 earnings per share for the current year.

Institutional Investors Weigh In On BioNTech

Hedge funds have recently added to or reduced their stakes in the stock. Dodge & Cox increased its holdings in shares of BioNTech by 315.7% in the 3rd quarter. Dodge & Cox now owns 3,647,091 shares of the company’s stock worth $359,676,000 after acquiring an additional 2,769,654 shares during the period. BNP Paribas Financial Markets raised its stake in BioNTech by 43.0% during the 4th quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock valued at $150,235,000 after acquiring an additional 474,796 shares in the last quarter. GSK plc bought a new position in shares of BioNTech in the fourth quarter worth $84,711,000. Franklin Resources Inc. increased its holdings in shares of BioNTech by 76.8% during the second quarter. Franklin Resources Inc. now owns 751,998 shares of the company’s stock valued at $80,065,000 after purchasing an additional 326,556 shares during the period. Finally, Invesco Ltd. grew its position in BioNTech by 5.6% in the 2nd quarter. Invesco Ltd. now owns 681,100 shares of the company’s stock valued at $72,517,000 after buying an additional 35,958 shares in the last quarter. 15.52% of the stock is currently owned by institutional investors.

Trending Headlines about BioNTech

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: Strong balance sheet and pipeline: BioNTech reported €17.2B in cash and securities and outlined six late‑stage readouts and multiple oncology programs that management says derisk execution and support long‑term value creation. BioNTech corporate update and results
• Positive Sentiment: Potential upside from the co‑founders’ new venture: BioNTech will receive a minority stake in the new company and may earn milestone payments and royalties from contributed rights/technologies, creating optionality if next‑gen mRNA assets succeed. Co‑founders launch new mRNA venture
• Neutral Sentiment: Mixed quarter — EPS beat but revenue dynamics weak: BioNTech beat EPS estimates (reported ($0.39) vs. ($0.57) expected) and posted revenue of $1.06B (above consensus), but revenue is down ~24% YoY and adjusted losses were reported. Investors will parse beats vs underlying growth trends. Q4 2025 earnings highlights
• Neutral Sentiment: Analyst repositioning: Jefferies cut its price target (from $151 to $138) but kept a buy rating — signaling some analyst confidence on long‑term upside despite nearer‑term risks. Analyst PT change
• Negative Sentiment: Cofounders’ exit raises governance and execution concerns: Founders Ugur Sahin and Özlem Türeci will leave by end‑2026 to start a new company; BioNTech will transfer certain rights/tech, prompting investor worry about talent loss and strategic disruption. Reuters: founders to leave
• Negative Sentiment: Weaker FY2026 revenue guidance: Management cut 2026 revenue guidance to roughly €2.0–2.3B (below Street expectations), increasing near‑term growth concerns and pressuring sentiment. Full results and guidance
• Negative Sentiment: Regulatory/legal overhang: A plaintiff firm (Johnson Fistel) is investigating potential claims against BioNTech’s executives, adding legal risk and headline volatility. Johnson Fistel investigation notice
• Negative Sentiment: Immediate market reaction: Multiple outlets report a steep intraday share decline after the combined news of the founder exit and weaker outlook, reflecting selling pressure and short‑term sentiment deterioration. Market reaction coverage

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.